-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
Avalo Therapeutics Trading Down 0.5 %
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
Get Avalo Therapeutics alerts:Analysts Set New Price Targets
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
Institutional Investors Weigh In On Avalo Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new stake in Avalo Therapeutics in the second quarter worth about $506,000. Goldman Sachs Group Inc. lifted its holdings in shares of Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Avalo Therapeutics during the third quarter worth about $52,000. Finally, Leo Brokerage LLC acquired a new stake in shares of Avalo Therapeutics during the first quarter worth about $45,000.About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Recommended Stories
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decline of 27.5% from the October 15th total of 48,700 shares. Based on an average daily volume of 31,100 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short.
阿瓦洛治療公司(納斯達克代碼：AVTX-GET評級)在10月份看到空頭股數的銷售額大幅下降。截至10月31日，空頭股數共有35,300股，較10月15日的48,700股下降了27.5%。以日均成交量31,100股計算，目前短息比率為1.1天。目前，該公司0.4%的股票被賣空。
Avalo Therapeutics Trading Down 0.5 %
Avalo治療公司股價下跌0.5%
NASDAQ AVTX traded down $0.03 during trading on Monday, hitting $5.77. The company's stock had a trading volume of 6,065 shares, compared to its average volume of 41,556. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 0.97. The business's 50 day simple moving average is $4.92 and its 200-day simple moving average is $5.19. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $27.84.
在週一的交易中，納斯達克AVTX股價下跌0.03美元，至5.77美元。該公司股票的成交量為6,065股，而其平均成交量為41,556股。該公司的債務權益比為5.23，流動比率為1.07，速動比率為0.97。該業務的50日簡單移動均線切入位為4.92美元，200日簡單移動均線切入位為5.19美元。Avalo Treateutics的股價為52周低點2.42美元，52周高點27.84美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, Oppenheimer lowered their price target on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday, November 9th.
另外，奧本海默在11月9日星期三的一份報告中將Avalo治療公司的目標價從17.00美元下調至10.00美元。
Institutional Investors Weigh In On Avalo Therapeutics
機構投資者看好Avalo治療公司
About Avalo Therapeutics
關於Avalo Treateutics
(Get Rating)
(獲取評級)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics，Inc.是一家臨牀階段的精密藥物公司，為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向療法。該公司開發了AVTX-002，這是一種完全人類抗光的單抗，正在進行第二階段臨牀試驗，用於治療非嗜酸性哮喘以及炎症性腸道疾病，包括中到重度克羅恩病和潰瘍性結腸炎；以及第三階段臨牀試驗，用於治療新冠肺炎急性呼吸窘迫綜合徵。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- 免費獲取StockNews.com關於Avalo治療公司(AVTX)的研究報告
- 是時候與Joby Aviation的電動汽車創新一起兜風了嗎？
- 在100美元的理髮之後，Catalent是一個超賣的製藥公司嗎？
- 泰森食品是不是太便宜了，不容忽視？
- Alphabet股票提供難得的買入機會
- 太陽能電池製造商安相清理買入點位：漲勢能否守住？
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avalo治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧